Miniature inhalation therapy platform using surface acoustic wave microfluidic atomization
Miniature inhalation therapy platform using surface acoustic wave microfluidic atomization
复制标题
DOI：
10.1039/b903575c
复制
发表时间：
2009-01-01
期刊：
影响因子：
6.1
通讯作者：
Spiccia, Leone
中科院分区：
文献类型：
--
作者：
Qi, Aisha;Friend, James R.;Spiccia, Leone
肺部给药需要将药物制剂以吸入颗粒或液滴的形式直接输送到肺部的下呼吸道和肺泡，这与治疗呼吸系统疾病的其他方法相比具有明显的优势：药物可以直接输送到炎症部位，从而减少了全身暴露的需要和不良反应的可能性。然而，很难在狭窄的单分散尺寸范围内（1-10 μ m）产生药物溶液滴，以沉积在下呼吸道和肺泡中。在这里，我们展示了使用表面声波微流体雾化作为一种有效的方法来产生含有模型药物的适当气溶胶，短效β(2)激动剂沙丁胺醇，用于治疗哮喘。产生的平均气溶胶直径为2.84 +/- 0.14 μ m，完全在最佳尺寸范围内，由双级撞击肺模型证实，表明提供给雾化器的约70%至80%的药物沉积在肺内。我们的初步研究探讨了如何通过表面张力、粘度和输入功率来控制气溶胶直径和肺输送效率，并指出了哪些因素如流体密度是无关的。即使在1-1.5 W的适度功率范围内，SAW雾化也为通过肺部途径输送药物提供了可行且高效的通用雾化平台，用于治疗各种疾病。对气溶胶大小的控制、低功率要求、高输送效率和系统的小型化共同表明，所提出的平台代表了当前与微流体技术兼容的雾化器的一个有吸引力的替代方案。
Pulmonary drug administration requires direct delivery of drug formulations into the lower pulmonary tract and alveoli of the lung in the form of inhaled particles or droplets, providing a distinct advantage over other methods for the treatment of respiratory diseases: the drug can be delivered directly to the site of inflammation, thus reducing the need for systemic exposure and the possibility of adverse effects. However, it is difficult to produce droplets of a drug solution within a narrow monodisperse size range (1-10 mu m) needed for deposition in the lower pulmonary tract and alveoli. Here, we demonstrate the use of surface acoustic wave microfluidic atomization as an efficient means to generate appropriate aerosols containing a model drug, the short-acting beta(2) agonist salbutamol, for the treatment of asthma. The mean aerosol diameter produced, 2.84 +/- 0.14 mu m, lies well within the optimum size range, confirmed by a twin-stage impinger lung model, demonstrating that approximately 70 to 80% of the drug supplied to the atomizer is deposited within the lung. Our preliminary study explores how to control the aerosol diameter and lung delivery efficiency through the surface tension, viscosity, and input power, and also indicates which factors are irrelevant-like the fluid density. Even over a modest power range of 1-1.5 W, SAW atomization provides a viable and efficient generic nebulization platform for the delivery of drugs via the pulmonary route for the treatment of various diseases. The control offered over the aerosol size, low power requirements, high delivery efficiency, and the miniaturization of the system together suggest the proposed platform represents an attractive alternative to current nebulizers compatible with microfluidic technologies.